An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Arcus Biosciences (RCUS) will host a conference call to discuss its first-quarter 2024 financial results and pipeline update. The call will take place on May 8th, 2024, at 1:30 PM PT / 4:30 PM ET. Investors can dial in or access the webcast on the company's website.
Arcus Biosciences (RCUS) organizzerà una conferenza telefonica per discutere i risultati finanziari del primo trimestre del 2024 e l'aggiornamento del pipeline. La chiamata avrà luogo l'8 maggio 2024 alle 13:30 PT / 16:30 ET. Gli investitori possono partecipare telefonicamente o accedere alla trasmissione web sul sito web dell'azienda.
Arcus Biosciences (RCUS) realizará una llamada de conferencia para discutir los resultados financieros del primer trimestre de 2024 y la actualización de su cartera. La llamada se llevará a cabo el 8 de mayo de 2024 a la 1:30 PM PT / 4:30 PM ET. Los inversores pueden unirse por teléfono o acceder a la transmisión web en el sitio web de la compañía.
아커스 바이오사이언스 (RCUS)가 2024년 1분기 재무 결과 및 파이프라인 업데이트에 대해 논의하기 위한 컨퍼런스 콜을 주최할 예정입니다. 이 통화는 2024년 5월 8일 오후 1시 30분 PT / 오후 4시 30분 ET에 진행됩니다. 투자자는 전화로 참여하거나 회사 웹사이트에서 웹캐스트를 접속할 수 있습니다.
Arcus Biosciences (RCUS) organisera une conférence téléphonique pour discuter des résultats financiers du premier trimestre 2024 et de la mise à jour de son pipeline. L'appel aura lieu le 8 mai 2024 à 13h30 PT / 16h30 ET. Les investisseurs peuvent composer le numéro de téléphone ou accéder à la webdiffusion sur le site web de l'entreprise.
Arcus Biosciences (RCUS) wird einen Telefonkonferenz abhalten, um die Finanzergebnisse des ersten Quartals 2024 und das Update zum Produktportfolio zu besprechen. Der Anruf findet am 8. Mai 2024 um 13:30 Uhr PT / 16:30 Uhr ET statt. Investoren können sich telefonisch einwählen oder den Webcast auf der Website des Unternehmens abrufen.
Positive
None.
Negative
None.
HAYWARD, Calif.--(BUSINESS WIRE)--
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will host a conference call and webcast on Wednesday, May 8th, 2024 at 1:30 PM PT / 4:30 PM ET to discuss details of the Company’s financial results and pipeline update for the quarter ended March 31st, 2024.
Investors interested in listening to the conference call may do so by dialing (404) 975-4839 (local) or (833) 470-1428 (toll-free), using Access Code: 034427. To access the live webcast and accompanying slide presentation, please visit the “Investors & Media” section of the Arcus Biosciences website at www.arcusbio.com. A replay of the webcast will be available following the live event.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b receptor), HIF-2a, CD39 and AXL. For more information about Arcus Biosciences’ clinical and preclinical programs, please visit www.arcusbio.com.